New York (MedscapeWire) Apr 11 — Scientists at Bristol-Myers Squibb have identified a promising new collection of drugs that may indefinite quantity strong candidates for the intervention of erectile dysfunction (also known as impotence) that may be more potent and have fewer side effects than the popular viagra (sildenafil, Pfizer Inc), they say.
The findings appeared in the April 6 payoff of the Account book of Medicinal Chemical science.
Although none of these compounds has been tested in humans, the researchers believe that the line concentration points toward promising new treatments for erectile dysfunction.
The gear reliable oral therapy for the care of erectile dysfunction, sildenafil has surged in popularity since its beginning 2 assemblage ago.
It helps maintain an sexual arousal by blocking the mechanism of an enzyme called phosphodiesterase type 5 in penile paper.
Phosphodiesterase has several different forms.
Researchers believe that sildenafil lacks particularity for certain forms of the enzyme — notably, type 1 and type 6 — and that nonselective encirclement of these enzymes may causation some of the drug’s adverse effects, especially facial nerve flushing and visual disturbances.
In an campaign to create a superior drug, the researchers identified a fiction year of phosphodiesterase inhibitors that act on the same aim as sildenafil .
Using an animal tissue paper leader for erectile dysfunction, the researchers tested these compounds in the research laboratory and found that they were as potent as viagra in achieving alleviation of the smooth sinew tissues.